Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib
Internal and Emergency Medicine · 2024
DOI: 10.1007/s11739-024-03578-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal and Emergency Medicine, 2024. Verfasst von Bernardo Stefanini und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Bologna, 40138, Bologna, Italy. bernardo.stefanini@studio.unibo.it. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms, Angiogenesis Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.
Abstract (Originalsprache)
Antiangiogenics are associated with an increased risk of major adverse cardiac and cerebrovascular events (MACE). The identification of at-risk subjects is relevant in the case of hepatocellular carcinoma (HCC), for which anti-angiogenic TKIs and bevacizumab are used in first and subsequent lines of therapy, to select alternative drugs for patients with excessive risk. We verified the ability to predict MACE in sorafenib-treated patients of the 2022 European Society of Cardiology (ESC-2022) score for anti-angiogenics and the recently proposed CARDIOSOR score. A retrospective analysis was conducted of prospectively collected data of the ARPES and ITA.LI.CA databases. All patients received sorafenib for unresectable HCC from 2008 to 2018. Baseline information to calculate the ESC-2022 and CARDIOSOR scores and registration of evolutive events (including MACE) were available for all patients. The predictive ability of both scores was verified using competing risk regressions and tests for goodness of fit. This study included 843 patients (median follow-up 11.3 months). Thirty-four (4.0%) patients presented a MACE. The four-tier ESC-2022 classification showed a progressive risk increase for every class (cumulative risk 1.7%, 2.7%, 4.3%, and 15.0% in the low, medium, high, and high-risk tiers, respectively). The dichotomous CARDIOSOR scale identified a high-risk group with a fourfold increased risk of MACE (sHR 4.66, p = 0.010; cumulative risk 3.8% and 16.4%). ESC-2022 showed a better goodness of fit compared to the CARDIOSOR score [C-index 0.671 (0.583–0.758) vs 0.562 (0.501–0.634), p = 0.021], but this gap was eliminated using the linear version of CARDIOSOR. Both the ESC-2022 and CARDIOSOR scores discriminated patients at increased risk for MACE. The use of these scores in clinical practice should be encouraged, since therapeutic measures can mitigate the cardiovascular risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, University of Bologna, 40138, Bologna, Italy. bernardo.stefanini@studio.unibo.it.
- Department of Medical and Surgical Sciences, University of Bologna, 40138, Bologna, Italy.
- Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
- Unit of Semeiotics, Liver and Alcohol-Related Diseases, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
- Liver Unit, Department of Transplantation, Cardarelli Hospital, Naples, Italy.
- Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy.
ORCID-Profile: Bernardo Stefanini
Förderung
- Alma Mater Studiorum - Università di Bologna
Zitieren
APA
Stefanini, B., Tovoli, F., Trevisani, F., Marseglia, M., Di Costanzo, G. G., Cabibbo, G., Sacco, R., Pellizzaro, F., Pressiani, T., Chen, R., Ponziani, F. R., Foschi, F. G., Magini, G., Granito, A., Piscaglia, F., & Italian Liver Cancer (ITA.LI.CA) group (2024). Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib. Internal and Emergency Medicine. https://doi.org/10.1007/s11739-024-03578-8
Vancouver
Stefanini B, Tovoli F, Trevisani F, Marseglia M, Di Costanzo GG, Cabibbo G, et al. Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib. Internal and Emergency Medicine. 2024. doi:10.1007/s11739-024-03578-8
BibTeX
@article{Stefanini2024,
author = {Stefanini, Bernardo and Tovoli, Francesco and Trevisani, Franco and Marseglia, Mariarosaria and Di Costanzo, Giovan Giuseppe and Cabibbo, Giuseppe and Sacco, Rodolfo and Pellizzaro, Filippo and Pressiani, Tiziana and Chen, Rusi and Ponziani, Francesca Romana and Foschi, Francesco Giuseppe and Magini, Giulia and Granito, Alessandro and Piscaglia, Fabio and Italian Liver Cancer (ITA.LI.CA) group, Italian Liver Cancer (ITA.LI.CA) group},
title = {Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib},
journal = {Internal and Emergency Medicine},
year = {2024},
doi = {10.1007/s11739-024-03578-8}
}
EUVIMED